An observational study in Generalized Myasthenia Gravis and Anti-AChR Antibody Positive, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 23 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is one of 4 that started in 2025, is one of 6 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 16th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 18+
AstraZeneca · Sites in Russia
Ages 18+
AstraZeneca · Sites in Poland
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 40 is below the median of 130 across 105 observational studies indexed under Myasthenia Gravis.
Median enrollment 20 across the 13 interventional studies, 263 across the 6 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
4 of the studies in Myasthenia Gravis by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT07596784Phase 3Alexion Pharmaceuticals, Inc.Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | 2027-08-24 |
| NCT06967480Alexion Pharmaceuticals, Inc.Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | 2027-06-30 |
| NCT07221838Alexion Pharmaceuticals, Inc.A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | 2027-08-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Patients with anti-AChR antibody positive, generalized, myasthenia gravis elegible to Ravulizumab treatment with a disease duration from onset equal or less than 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of MG confirmed by:
One of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Ravulizumab until Week 50 ± 14 days after baseline or until discontinuation.
Drug: Ravulizumab
Participants will receive Ravulizumab.
Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 50
Time frame: Week 50
Change From Baseline in MG-ADL Total Score at Week 50
Time frame: Baseline, Week 50
MG-ADL Total Score at Weeks 2, 10, and 26
Time frame: Weeks 2, 10, and 26
Change From Baseline in MG-ADL Total Score at Weeks 2, 10 and 26
Time frame: Baseline, Weeks 2, 10 and 26
Percentage of Participants With >=2- Point Reduction From Baseline in MG-ADL Total Score at Weeks 2, 10, 26, and 50
Time frame: Baseline, Weeks 2, 10, 26, and 50
Quantitative Myasthenia Gravis (QMG) Total Score at Weeks 2, 10, 26, and 50
Time frame: Weeks 2, 10, 26, and 50
Change From Baseline in QMG Total Score at Weeks 2, 10, 26 and 50
Time frame: Baseline, Weeks 2, 10, 26 and 50
Percentage of Participants With >=3- Point Reduction From Baseline in QMG Total Score at Weeks 2, 10, 26, and 50
Time frame: Baseline, Weeks 2, 10, 26, and 50
Myasthenia Gravis Composite (MGC) Total Score at Weeks 2, 10, 26, and 50
Time frame: Weeks 2, 10, 26, and 50
Change From Baseline in MGC Total Score at Weeks 2,10, 26 and 50
Time frame: Baseline, Weeks 2, 10, 26 and 50
Percentage of Participants With >=3- Point Reduction From Baseline in MGC Total Score at Weeks 2, 10, 26 and 50
Time frame: Baseline, Weeks 2, 10, 26, and 50
Myasthenia Gravis Quality of Life 15-Item Scale - Revised (MG-QoL15r) Total Score at Weeks 10, 26, and 50
Time frame: Weeks 10, 26, and 50
Change From Baseline in MG-QoL15r Total Score at Weeks 10, 26 and 50
Time frame: Baseline, Weeks 10, 26 and 50
Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 10, 26, and 50
Time frame: Weeks 10, 26, and 50
Change From Baseline in HADS Total Score at Weeks 10, 26 and 50
Time frame: Baseline, Weeks 10, 26 and 50
Insomnia Severity Index Scale (ISI) Total Score at Weeks 10, 26, and 50
Time frame: Weeks 10, 26, and 50
Change From Baseline in ISI Total Score at Weeks 10, 26 and 50
Time frame: Baseline, Weeks 10, 26 and 50
Pain Visual Analogue Scale (Pain VAS) Total Score at Weeks 2, 10, 26, and 50
Time frame: Weeks 2, 10, 26, and 50
Change From Baseline in Pain VAS Total Score at Weeks 2, 10, 26 and 50
Time frame: Baseline, Weeks 2, 10, 26 and 50
Percentage of Participants With Mean Dose Reduction From Baseline of Corticosteroids and Immunosuppressants (ISTs) Treatment at Weeks 2, 10, 26, and 50
Time frame: Baseline, Weeks 2, 10, 26, and 50
Percentage of Participants in Different ISTs Status at Baseline, and at Weeks 2, 10, 26, and 50
Time frame: Baseline, Weeks 2, 10, 26, and 50
Number of Clinical Deterioration Events
Time frame: Baseline, Weeks 2, 10, 26, and 50
Percentage of Participants With Minimal Symptom Expression at Weeks 2, 10, 26, and 50
Time frame: Weeks 2, 10, 26, and 50
Institute For Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) Score at Weeks 10, 26, and 50
Time frame: Weeks 10, 26, and 50
Change From Baseline in iMTA iPCQ Score at Weeks 10, 26 and 50
Time frame: Baseline, Weeks 10, 26 and 50
Biomarkers analyses (complement system proteins, interleukins and miRNA serum levels)
Time frame: Baseline, Week 10, 26, and 50
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 62 observational studies under Myasthenia Gravis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexion Pharmaceuticals, Inc. →